Guangyang Weng

4PUBLICATIONS
23CO-AUTHORS
Traditional Chinese medicine and treatmentsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Nov 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.

Guopan Yu, Yu Zhang, Sijian Yu

|Feb 09, 2024
Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.

Guangyang Weng, Jingya Huang, Na An

|Sep 18, 2023
Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.

Guangyang Weng, Jingya Huang, Xin He

|Oct 26, 2022
Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.

Guangyang Weng, Yu Zhang, Guopan Yu

Pageof 1

Frequent Collaborators

2 joint publications

Hua Jin

2 joint publications

Qifa Liu

1 joint publications

Guopan Yu

1 joint publications

Yu Zhang